LRRK2 Monoclonal Antibody

Catalogue Numbers: MB67126-50, MB67126-100

Sizes: 50µl, 100µl

Product: Mouse IgG1. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide.

Swiss-Prot: Q5S007

Host: Mouse

Reactivity: Human, Mouse

Applications: WB

All Applications: WB (1/500 - 1/1000)

Background: Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmarks of PD are progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem. Research studies have shown various genes and loci are genetically linked to PD including α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2.
Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. Research studies have linked at least 20 LRRK2 mutations to PD, with the G2019S mutation being the most prevalent. The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length that leads to progressive neurite loss and decreased neuronal survival . Researchers are currently testing the MLK inhibitor CEP-1347 in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD.

Purification and Purity: This antibody is purified through a protein G column.

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Recognizes endogenous levels of LRRK2 protein.

Extra Notes: Western blot analysis of LRRK2 expression in mouse brain (A) whole cell lysates.

Bioworld Molecular Weight: ~ 180 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Name: PARK8; Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin

Immunogen: Recombinant fusion protein of human LRRK2. The exact sequence is proprietary.

Conjugate: Unconjugated

Modification: Unmodified